• September 26, 2020

Biotech Company Pascal Biosciences and SōRSE Technology Announce Partnership for Cannabinoid Drug Development and Cancer Clinical Trials - Odessa American: Business

e-Edition Subscribe

Biotech Company Pascal Biosciences and SōRSE Technology Announce Partnership for Cannabinoid Drug Development and Cancer Clinical Trials

Print
Font Size:
Default font size
Larger font size

Posted: Tuesday, September 15, 2020 5:00 am

SEATTLE & VANCOUVER, British Columbia--(BUSINESS WIRE)--Sep 15, 2020--

Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and SōRSE Technology Corporation (“SōRSE”) have entered into a Collaborative Research Agreement to advance Pascal’s PAS-393 into clinical testing. Pascal and SōRSE will share their respective technologies to test the cannabinoid PAS-393 in human volunteers, enabling testing of cancer patients treated with checkpoint inhibitors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005095/en/

As initially announced last March, this partnership leverages SōRSE’s industry-leading formulation technology with Pascal’s proprietary cannabinoid programs for clinical trials. This will be the first pharmaceutical use of the novel formulation technology developed by SōRSE. The agreement will include Pascal’s intellectual property, which covers the use of cannabinoids in cancer patients treated with checkpoint inhibitors.

SōRSE currently sells and licenses a proprietary water-soluble cannabinoid emulsion technology (patent-pending) that enables increased bioavailability, accurate dosing, and more than 12 months’ shelf stability. Pascal and SōRSE scientists will optimize a cannabinoid formulation for human subjects and will then test the formulated PAS-393 in volunteers. SōRSE will provide $750,000 in research funding to Pascal throughout the 15-month collaboration and will pay for related research expenditures.

Following characterization of safety and pharmacology in a Phase 1a clinical trial, Pascal and SōRSE may elect to continue clinical development as equal partners in a Phase 1b cancer trial in combination with a checkpoint inhibitor. Dr. Gray will present scientific data this September 15th at the 3rd Annual International Cannabinoid-Derived Pharmaceutical Conference occurring in Boston, MA; the topic of his presentation is “Identifying and Validating Mechanism of Action In vivo / vitro.”

“At SōRSE, we’re driven by our mission to help people better their lives through superior cannabinoid ingredients and delivery methods,” said SōRSE CEO Howard Lee. “We were thrilled when Pascal Biosciences reached out to us in the summer of 2019 asking to use our emulsion in their research study on immune recognition markers on cancer cells. Today, we are excited to continue to support pharmaceutical studies of cannabinoids with Pascal and other world-class researchers.”

SōRSE intends to collaborate with other researchers and product developers to study cannabinoids in other medical applications. Pascal will continue to pursue other non-cancer indications for PAS-393.

“This is an impressive step forward for both Pascal and SōRSE, and hopefully our product will be a significant help to patients,” commented Dr. Patrick Gray, CEO of Pascal Biosciences. “This will be the first clinical trial for each company, and we look forward to a long, fruitful relationship.”

About Pascal Biosciences Inc.

Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics. Pascal's leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. For more information, visit www.pascalbiosciences.com.

About PAS-393

Pascal recently discovered the unique capacity of its cannabinoid drug, PAS-393, to reverse a common immune-evading strategy adopted by many metastatic cancers. Thus, treatment with PAS-393 may restore the ability of the immune system to recognize and eliminate cancer cells. This activity is especially important for immune checkpoint inhibitors, which depend upon immune recognition of cancer for their efficacy. Pascal is advancing PAS-393 as a combination therapy with checkpoint inhibitors for the 50% or more of cancer patients not currently helped by the checkpoint inhibitors.

About SōRSE Technology Corporation

SōRSE Technology Corporation is a water-soluble emulsion technology designed for product developers to provide consumers with a better, more consistent cannabinoid experience with greater bioavailability, near-perfect dosing, shelf-stability, and safe ingredients. Its patent-pending technology converts oil into SōRSE, a proprietary water-soluble emulsion, for infusing CBD and other functional ingredients into beverages, food items, topicals, and medical applications. SōRSE Technology currently powers more than 45 leading products in the CBD space.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200915005095/en/

CONTACT: SōRSE Technology Press:

Jon Lindsay Phillips

RLM PR

SorseTech@rlmpr.com

+1-646-828-8566

KEYWORD: WASHINGTON UNITED STATES NORTH AMERICA CANADA

INDUSTRY KEYWORD: BIOTECHNOLOGY ALTERNATIVE MEDICINE INFECTIOUS DISEASES HEALTH CLINICAL TRIALS

SOURCE: SōRSE Technology Corporation

Copyright Business Wire 2020.

PUB: 09/15/2020 06:00 AM/DISC: 09/15/2020 06:00 AM

http://www.businesswire.com/news/home/20200915005095/en

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Clear
86°
Humidity: 49%
Winds: S at 17mph
Feels Like: 88°

Your Extended Forecast

Tomorrow

weather
High 99°/Low 65°
Clear. Lows overnight in the mid 60s.

sunday

weather
High 101°/Low 57°
Mainly sunny. Highs 99 to 103F and lows in the upper 50s.

monday

weather
High 73°/Low 46°
Windy with a mix of sun and clouds. Highs in the low 70s and lows in the mid 40s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.